Four Key Genes Linked to Worse Gastric Cancer Outcomes

The four key genes linked to worse gastric cancer outcomes, as identified by new research from Brazil, are BRCA2, CDH1, RHOA, and TP53. Here’s a detailed breakdown of their significance:

1. BRCA2

• Role in Cancer: BRCA2 is well-known for its involvement in breast and ovarian cancers. It plays a critical role in DNA repair, and mutations in this gene can lead to genomic instability, which promotes cancer development.
• Impact on Gastric Cancer: In the context of gastric cancer, BRCA2 mutations are associated with higher chances of recurrence and death, contributing to worse disease-free and overall survival.

2. CDH1

• Role in Cancer: CDH1 is linked to hereditary diffuse gastric cancer and encodes a protein called E-cadherin, which is important for cell adhesion. Mutations in CDH1 disrupt cell-to-cell communication, making it easier for cancer cells to invade and metastasize.
• Impact on Gastric Cancer: CDH1 mutations are strongly associated with aggressive forms of gastric cancer, leading to poorer prognoses.

3. RHOA

• Role in Cancer: RHOA is involved in regulating cell shape, movement, and the cytoskeleton. Alterations in this gene can promote cancer cell migration and invasion.
• Impact on Gastric Cancer: Mutations in RHOA contribute to cancer progression by enhancing the ability of cancer cells to spread, worsening outcomes for patients.

4. TP53

• Role in Cancer: TP53 is one of the most frequently mutated genes in all human cancers. It encodes the p53 protein, which acts as a tumor suppressor by regulating cell cycle arrest, DNA repair, and apoptosis.
• Impact on Gastric Cancer: Mutations in TP53 disable its tumor-suppressing functions, allowing cancer cells to grow uncontrollably, leading to more aggressive disease and worse survival rates.

Key Findings from the Research:

• Independent and Combined Effects: Each of these genes is individually associated with a poorer prognosis in gastric cancer. However, the presence of mutations in multiple genes further increases the risk of recurrence and death.
• Prevalence: About one-third of the patients in the study carried mutations in at least one of these genes.
• Treatment Implications: Even with surgery, chemotherapy, and immunotherapy, patients with these mutations had worse disease-free and overall survival compared to those without them.

Implications for Precision Oncology:

• The study suggests that gastric cancer can arise through multiple pathways, and some cases are inherently more aggressive due to these genetic mutations.
• Personalized Treatment: Identifying these mutations in patients can help guide precision oncology. High-risk patients with these mutations may benefit from more aggressive treatment strategies, while low-risk patients could avoid unnecessary side effects from intensive therapies.

This research highlights the importance of genetic testing in gastric cancer to improve prognostic accuracy and tailor treatments to individual patients.